Recordati

REC · Euronext Milan · Italy

Public Market Listing

RECEuronext Milan

Euronext Milan primary exchange listing

Live quotes, historical charts, and market capitalization for Recordati are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
3Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
Omega-3 fatty acid (EPA)Small molecule
Atherosclerotic Cardiovascular DiseaseSevere Hypertriglyceridemia
Lomitapide(Juxtapid)
Approved
MTPSmall molecule
Homozygous Familial Hypercholesterolemia
Zilganersen(Zanvastro)
Approved
GFAP pre-mRNARNA / oligonucleotide
Alexander Disease
Preclinical / Unstaged
L-type calcium channels (Cav1.2)Small molecule
Hypertension

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 October 2026Topline resultIcosapent EthylEMT2 Phase 3 trial results: primary PFS endpoint not met, OS improved
22 September 2026FDA action dateZilganersenFDA PDUFA action date set for zilganersen
US, FDA · Source ↗
February 2026ApprovalLomitapideFDA updates Boxed Warning on Juxtapid (NDA203858)
US, FDA · FDA · Source ↗
22 September 2025Topline resultZilganersenPivotal study topline
Ionis Pharmaceuticals · Source ↗

Financial reports

No financial reports recorded.